• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Antipsychotic Drug Fights Leukemia in Model


Strategies that identify new uses for existing drugs have grown in popularity in recent years as a way of quickly developing new disease therapies. Zebrafish models are cost-effective platforms for rapidly conducting drug screens as well as basic stem cell, genetic, cancer and developmental research.

The study provides a prime example of finding new uses for older drugs. The findings also suggest that developing drugs that activate PP2A while avoiding perphenazine's psychotropic effects could help clinicians make much-needed headway against T-cell ALL and perhaps other tumors as well.

T-cell ALL, or T-ALL, is rarer and more aggressive than the B-cell form of ALL and has a relatively poor prognosis. Despite improvements in the treatments available, 20% of children and more than 50%of adults diagnosed with T-ALL succumb to it.

Read the full story here: http://bit.ly/1arLGU3

Source: Drug Discovery and Development

A 50-year-old antipsychotic drug can combat a difficult-to-treat form of acute lymphoblastic leukemia (ALL) in zebrafish, according to new a study led by Harvard Medical School researchers. The drug, perphenazine, works by turning on a cancer-suppressing enzyme called PP2A and causing malignant tumor cells to self-destruct.

Related Videos
Amitkumar Mehta, MD, MBA
Alma Habib, MD
Jennifer Vaughn, MD, The Ohio State University Comprehensive Cancer Center
Sarah Wall, MD
Adam Kittai MD
Fabian Lang, MD, Goethe Hospital, Germany
Wojciech Jurczak, MD, PhD
Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany
Dr Fabian Lang of Goethe University Hospital in Frankfurt, Germany
Related Content
© 2024 MJH Life Sciences
All rights reserved.